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Abstract
Aim To evaluate the effect of system interventions (formalized data collection and 100% coverage of medications and
supplies) combined with physician and/or patient education on therapeutic indicators and costs in Type 2 diabetes.
Methods This was a randomized 2 9 2 design in public health, social security or private prepaid primary care clinics in
Corrientes, Argentina. Thirty-six general practitioners and 468 adults with Type 2 diabetes participated. Patients of nine
participating physicians were selected randomly and assigned to one of four structured group education programmes
(117 patients each): control (group 1), physician education (group 2), patient education (group 3), and both physician
education and patient education (group 4), with identical system interventions in all four groups. Outcome measures
included HbA1c, BMI, blood pressure, fasting glucose, lipid profile, drug consumption, resource use and patient well-
being at baseline and every 6 months up to 42 months.
Results HbA1c decreased significantly from 4 mmol/mol to 10 mmol/mol by 42 months (P < 0.05); the largest and
more consistent decrease was in the groups where patients and physicians were educated. Blood pressure and
triglycerides decreased significantly in all groups; the largest changes were recorded in the combined education group.
The World Health Organization-5 Lowe score showed significant improvements, without differences among groups. The
lowest treatment cost was seen in the combined education group.
Conclusions In a primary care setting, educational interventions combined with comprehensive care coverage resulted
in long-term improvement in clinical, metabolic and psychological outcomes at the best cost-effectiveness ratio.
Diabet. Med. 00: 000–000 (2013)
Introduction
The chronic complications of Type 2 diabetes result in high
morbidity, mortality and socio-economic costs, which can be
significantly reduced by control of hyperglycaemia and
associated cardiovascular risk factors—a situation which is
unfortunately achieved infrequently [1–10]. Such a situation
results from failure to (1) pay for preventive interventions
[11], (2) achieve adequate knowledge and skills by practi-
tioners [11–13], (3) have adequate access to care and self-
care education, (4) address the psychological impact of
diabetes [14] and (5) appropriately monitor outcomes and
make adjustments [9,15].
Whereas both physician and patient education significantly
improve outcomes [16–18], little is known about the relative
effectiveness and costs when system changes and educational
interventions are combined [16]. Further, a recent large
review on the impact of education upon Type 2 diabetes
outcomes concluded that additional studies are needed to
support the potential long-term effect of education [19].
To address the limitation of our current understanding of
the relative costs and benefits of combining system changes
and education interventions, we implemented a 3-year
prospective intervention of diabetes education in primary
care settings of the city of Corrientes (PRODIACOR). The
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programme provided the structure and resources to deliver
quality diabetes care and analysed their relative effectiveness
on HbA1c (primary endpoint), blood pressure, lipid profile
and other psychological, clinical, metabolic and therapeutic
indicators, and treatment cost-effectiveness ratio.
Patients and methods
The study protocol was evaluated and approved by an
external ethical committee and participants gave informed
consent according to the guidelines from the International
Conference on Harmonization and the World Health Orga-
nization (WHO) good clinical practice standards. The study
design has been previously described [20]. Briefly, it was a
randomized 2 9 2 design trial to address the effectiveness of
system changes and the education of physicians and people
with diabetes.
Patient population
Included patients had Type 2 diabetes (using the American
Diabetes Association criteria) [21] for at least 2 years, and
were between 25 and 75 years of age. Patients with Type 1
diabetes, severe kidney disease, class III/IV heart failure,
blindness, cancer, alcohol or other drug addiction, and
incapacity to self-care were excluded.
Sample size estimation and patient recruitment
For sample size determination in each of the four groups, we
considered the change in HbA1c from baseline to the end of
the study as the primary outcome variable. We also consid-
ered that correlations of patients from the same physician
would be very small, from 0.20 to 0.30.
To estimate sample sizes, we applied a two-step approach.
First, we estimated the sample sizes required for the detection
of effects, assuming independence. This was carried out using
a two-sided test at the 5% level of significance and 80%
power using a paired t-test. The second step was to inflate the
sample size to account for non-independence. We chose to
increase the sample size at the first step by 25%, assuming
that there would be a 20% dropout or failure to follow up.
Hence, the sample size chosen was increased by 20% at the
second step. Assuming 1.5 as the standard deviation of the
change in HbA1c, 73 patients were required in each group at
the first step to detect a decrease of 0.5. This resulted in 111
patients for each group after adjusting for correlation and
dropout or failure to follow up.
Patients were recruited from healthcare institutions of the
three Argentinian health subsectors (public, social security
and prepaid system). The Corrientes team identified 100
potential participant physicians who saw more than 30
patients with diabetes per month and invited them to
participate in the study. Thirty-six physicians were recruited
(those with the largest number of patients seen per week) and
randomly allocated to each study group; thereafter, each
physician selected chronologically the first 13 patients
attending their office who met the inclusion criteria described
above. With this procedure, physicians identified 600
patients, from which 132 were excluded based on the
inclusion/exclusion criteria (Fig. 1). As assignment of
patients to each study group was nested by physician, all
the patients of an individual physician belonged to the same
group. Thus, there were four groups of 117 patients each: a
control group with neither patient nor physician education
(group 1), physician education (group 2), patient education
(group 3) and patient and physician education (group 4).
Educational strategies
We used the Diabetes Training Course for Physicians and the
Diabetes Structured Education Courses for People with
Type 2 Diabetes, whose characteristics and effectiveness
have been reported [17,22]. The Training Course for
Physicians consisted of a 25-structured module interactive
course conducted by trained diabetologist educators to
groups of 10–15 physicians in a highly interactive setting.
The modules had five thematic axes: (1) diagnosis, classifi-
cation and socio-economic impact, (2) associated cardiovas-
cular risk factors, (3) chronic complications, (4) control,
treatment and follow-up and (5) special conditions. Learning
was assessed by written evaluation after each module and a
final evaluation that included a practical test.
The Diabetes Structured Education Courses for People
with Type 2 Diabetes were conducted by trained educators
to groups of up to 10 ambulatory patients; they encouraged
interaction between the educator and participants. There
were four 90- to 120-min weekly teaching units and a
reinforcement session at 6 months. The first unit included
general concepts about Type 2 diabetes, symptoms of hypo-/
hyperglycaemia and glucose self-monitoring, with strong
emphasis on active patient participation and self-care. The
second unit was about the effect of obesity on insulin
sensitivity, the advantages of weight reduction and how to
classify and select foods according to their calories. The third
unit explained the importance of foot care and regular
physical activity. In the fourth unit, patients learnt ‘sick day’
rules and the examinations and laboratory tests necessary to
monitor diabetes care. Illustrated educational materials were
used and each patient received a programme book.
Data collection
Patient clinical, biochemical and therapeutic data before and
after PRODIACOR were recorded using the Physician Data
Form (Annual and Six-Month Clinical Record Form) and the
Feedback Report Form [8,23]. A software programme
compared HbA1c, serum lipids and blood pressure, and their
study goals on sequential encounters; a Feedback Report
for physicians and patients was generated, including
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recommendations about appropriate treatment to achieve
therapeutic goals. Psychological state was measured by a
Patient Questionnaire, based on the one used in the Diabetes
Advantage Program (DAP), which includes questions about
disease adjustment, and the World Health Organization-5
questionnaire [24].
Data collection was completed with the Personalized
Checkbook, the aim and content of which have been
published elsewhere [17]. The Checkbook is used to order
procedures, consultations, laboratory tests, prescription of
drugs and strips for glucose self-monitoring, and to record
and communicate results. It also records costs of procedures
and drug consumption.
Laboratory test performance
During the study period, all the laboratory tests were
performed at the same place in order to use a homogeneous
methodology, particularly HbA1c assay (immunoturbidimet-
ric procedure), and to avoid any possible inter-laboratory
variation. As, at the time of recruitment, many patients had
no recorded HbA1c measurement, and in some laboratories
HbA1c was being measured [20], we had to repeat all
measurements at time 0 (baseline); consequently, the average
values are different from those included in the original report.
Study and data management
The Corrientes Coordinator and the Central Coordinating
Center (CENEXA) oversaw the education courses and the
overall trial and maintained regular contact with the partic-
ipating physicians. A medical monitor reviewed physician
and patient performance and the quality of the data recorded
by the physicians at 6-month intervals for completeness; data
were then forwarded by mail to the Central Coordinating
Centre.
Resource utilization and costs
These data included all direct medical items used by each
programme participant; they were obtained from the utili-
zation and cost records of the participating health coverage
entities and the data in the Personalized Checkbooks.
Utilization was classified as follows: (1) hospitalizations,
(2) drugs and supplies, (3) diagnostic tests, (4) special studies
and (5) physician office visits. Very few hospitalizations
occurred, the highest (64% of total cost) and most precisely
recorded resource utilization was drug consumption. Subse-
quently, only this was used to measure the economic impact
of the different education strategies. Drug costs were assessed
from local retail prices (Alfabeta.net), adjusted to July 2004
using the health chapter of the local Consumer Price Index
from the Argentinian Statistics Office [33]. Costs were
expressed in Argentinian pesos ($) of July 2004 (Exchange
rate: $ 2.96 = 1 US Dollar).
The estimated initial drug cost for the control of HbA1c,
blood pressure and triglycerides and the reduction experi-
enced by each of these treatments within each treatment
group was used to construct marginal figures of cost ratio.
We calculated such ratio figures for each experimental group
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FIGURE 1 Flow diagram of the study. According to this schedule, in group 1, neither patients nor providers received education; in group 2, only
physicians received education; in group 3, only patients received education; and in group 4, both physicians and patients received education.
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by establishing the difference between the initial and final
value of every clinical/biochemical variable and the same
difference for the cost of its treatment. As initial and final
values were not identical, either for biological variables or
for treatment costs, for the sake of comparison we expressed
the total drug cost associated with the following decreases in
the main outcomes: $ by each 1% HbA1c, $ by each
10 mmHg systolic blood pressure or $ by each 10-mg/dl
triglyceride level. We did not include the costs of the
educational interventions themselves and the administrative
activities of the programme.
Statistical analysis
To estimate the effects of the different educative interven-
tions tested, we used the intention-to-treat analysis, widely
recommended as the preferred approach to the analysis of
most clinical trials [34]. For that purpose, the last observa-
tion carried forward was applied to missing data for the
primary endpoint. In addition, we used a multivariate
analysis of prognostic factors to predict the most likely
outcome in those lost to follow-up for any reason, imputa-
tion of outcomes by carrying the last known outcome status
forward and analysis of best-case and worst-case scenarios.
By doing that, we assumed that, although this analysis
cannot minimize bias introduced by loss to follow-up
[25,26], such loss would be within the expected rate and
similarly distributed among the different intervention groups.
Initial univariate differences among groups for quantita-
tive data were analysed by one-way ANOVA (Bonferroni
post hoc test). Factorial ANOVA and two-way ANOVA
models (Bonferroni post hoc tests) were used to assess the
differences among groups throughout the study. ANOVA
was also used to explore initial vs. end-of-study differences
among quantitative data. Differences among qualitative
measures were explored by the v2-test (Yates corrected).
P-values less than 0.05 were considered as significant (two-
tailed). The software used was CSS/Statistica version 6.0
(StatSoft Inc., Tulsa, OK, USA).
Ethical approval
This study was approved by the Fundacion de Estudios
Farmacologicos y de Medicamentos (FEFYM) Research
Ethics Committee.
Results
Population characteristics
Baseline data revealed a well-balanced subject allocation
within groups regarding gender, age, BMI, systolic blood
pressure, HbA1c and triglyceride levels (Table 1). Most
patients were overweight and their baseline systolic blood
pressure, fasting blood glucose, HbA1c and triglyceride levels
were above the target values recommended by international
guidelines.
As previously reported [20], acute diabetic complications
and hospitalizations were infrequent in our sample popula-
tion during the 42-month follow-up period, which is the
reason why these data were not included in the analysis.
Patient dropout
During the 42 months of the PRODIACOR study, of the
total number of patients included in this analysis, 125 (27%)
dropped out: 58 died (46%) and 67 (54%) abandoned the
study mainly because they moved to another city (65%).
Thus, only 23 out of 468 people abandoned the study for
personal reasons. Causes of death included neoplasms
(27%), cardiopathies (12%), infectious diseases (24%),
sudden death (10%), stroke (10%) and other causes (27%).
Despite that the dropout was slightly higher than originally
estimated to define the sample size, its number by group was
Table 1 Clinical and metabolic characteristics; baseline data
Group 1*
(control group)
Group 2 (physician
education)
Group 3 (patient
education)
Group 4 (patient and
physician education)
Age (years) 62.0  8.4 z 62.4  9.1 62.2  8.4 62.2  9.0
Gender (%) 67.5 70.1 66.7 62.4
Diabetes duration (years)* 9 (5–15) 10 (6–14) 8 (4–16) 8 (5–14)
BMI (kg/m2)* 29.3 (26.5–32.5) 30.0 (27.1–33.3) 29.0 (26.0–33.0) 30.1 (27.7–33.9)
Systolic blood pressure
(mmHg)
142  19 142  14 145  19 141  18.
Fasting blood glucose
(mg/dl)
147.5  48.9 142.4  43.6 146.6  43.8 145.3  57.9
HbA1c, mmol/mol (%) 62  9 (7.8  1.2) 58  12 (7.5  1.5) 62  11 (7.8  1.4) 61  10 (7.7  1.3)
Total cholesterol (mg/dl) 207.0  39.1 209.7  39.4 209.3  41.9 195.7  35.3
Triglycerides (mg/dl) 151.3  39.1 170.1  40.6 173.5  77.5 168.1  47.5
*Group 1, control group with no patient or physician education.
Data presented in the table show values recorded at time 0 of the study. In all cases, n = 117.
Data are mean  SD, except for *(median; interquartile range). In these instances, the P-value was estimated using the Kruskal–Wallis test.
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similar [control group with neither patient nor physician
education (group 1) 33; physician education (group 2) 28;
patient education (group 3) 31; patient and physicians
education (group 4) 33]; therefore, it did not affect the
power of statistical data analysis (Fig. 1). No significant
differences were recorded either in the baseline clinical or in
the metabolic characteristics of completers and those who
dropped out from the study.
Education
The knowledge acquired was measured in patients and
physicians before and after their courses using previously
validated multiple-choice questionnaires and is reported as a
percentage.
Patients
No differences among groups were detected regarding
initial knowledge (scores approximately 40%). After the
courses, a comparable increase was recorded in the patient
education group (group 3) and the patient and physician
education group (group 4) (73 vs. 77, respectively;
P = 0.8).
Physicians
There were no significant differences among groups at
baseline (average percentage score: 47%). After the course,
a comparable increase was observed in the physician
education group (group 2) and the patient and physician
education group (group 4) (81 vs. 83, respectively; P < 0.6
from baseline).
BMI
None of the PRODIACOR groups showed significant
changes in this variable.
HbA1c
There were no significant differences among groups at
baseline. HbA1c decreased significantly (P < 0.05) in the
control group with neither patient nor physician education
(group 1), the physician education group (group 2) and the
patient and physicians education group (group 4) by the end
of the study, attaining target values in the physician education
group (group 2) and the patient and physician education
group (group 4) (53 mmol/mol; ≤ 7%). The largest reduction
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FIGURE 2 Changes in HbA1c levels expressed in % (left axis) and mmol/mol (right axis). Each point represents the mean  SEM of the HbA1c levels
recorded in each group at a given time. Each point recorded in the abscissa was collected every 6 months. In every group, a significant difference was
observed between the value recorded at time 0 and 7 (42 months). This difference was larger in the patient and physician education group (group 4).
There were no significant differences among groups at time 0, while significant differences (P < 0.05) were recorded between groups at different
times: time 1, physician education (group 2) vs. patient education (group 3); time 2, physician education (group 2) vs. patient education (group 3);
time 6, physician education (group 2) vs. control group with no patient or physician education (group 1) and patient education (group 3) and
patient and physician education (group 4) vs. patient education (group 3); time 7, physician education (group 2) vs. no patient or physician
education (group 1) and patient education (group 3) and patient and physician education (group 4) vs. no patient or physician education (group 1)
and patient education (group 3). In each group, D values between time 0 and 7 are expressed as % and mmol/mol.
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was in the patient and physician education group (group 4)
(Fig. 2). Potential interaction was tested using the ANOVA
model and the interaction term that resulted was non-
significant (P = 0.331). There were also differences in the
HbA1c pattern of decrease among the study groups: the slope
of the curve only showed a continuous and consistent decrease
in the patient and physician education group (Fig. 2).
Blood pressure
Systolic blood pressure also had an inconsistent profile before
the intervention (Fig. 3). Although it decreased significantly
at the end of the study in all groups, the greatest decrease was
again recorded in the patient and physician education group
(group 4) (P < 0.05). When these values were sequentially
plotted, the most consistent decrease pattern was also
observed in that group (Fig. 3).
Serum triglyceride concentrations
Serum triglyceride concentrations showed an uneven pattern
before the intervention (Fig. 4). A significant decrease in
their values was recorded in the physician education group
(group 2), the patient education group (group 3) and the
patient and physician education group (group 4) at the end
of the study (P < 0.05), while the control group with no
patient or physician education (group 1) showed a signifi-
cant increase compared with baseline values. Again, the
largest and most continuous and consistent decrease was
observed in the patient and physician education group
(group 4) (Fig. 4).
Psychological aspects
TheWHO-5well-being questionnaire had low baseline scores
in all groups and, according to the score of Lowe et al. [27],
most patients needed psychological support (Table 2).
Although no special psychological care was provided, the
WHO-5 scores improved significantly by the end of the study
(P < 0.05), with no significant differences among groups.
Drug treatment costs
As mentioned before, during follow-up the greatest and most
precisely recorded resource consumption was drug consump-
tion (64% of total cost). Thus, we analysed only this item to
measure the economic impact of the different education
strategies. Within this cost, treatment of hyperglycaemia,
which includes the cost of blood glucose strips, was the most
expensive component, representing 48% of drug treatment
costs.
During the study period, the costs of drugs used to control
hyperglycaemia, hypertension and dyslipidaemia increased
unevenly but significantly in all groups (Table 3). As the
clinical and metabolic improvements recorded in each of the
intervention groups were of a different magnitude, it was not
easy to compare the cost-effectiveness of the drugs. To
overcome this problem, and as explained above (see Patients
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groups; significant differences (P < 0.05) were recorded between groups at different times: time 1, control group with no patient or physician
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and methods: Resource utilization and costs), we expressed
the incremental costs of drugs necessary to decrease an
arbitrary unit of each variable; i.e. what was the incremental
cost for a 10-mmol/mol (1%) decrease of HbA1c, a 10-
mmHg decrease in systolic blood pressure or a 10-mg/dl
decrease of triglyceride levels? Using this procedure, the best
cost-effective ratio for every variable measured was recorded
in the patient and physician education group (group 4)
(Table 3).
Discussion
Our data show that clinical, metabolic and psychological
indicators improved significantly after implementing differ-
ent targeted educational interventions at the primary care
level in a population with a median 10-year duration of
Type 2 diabetes over a 42-month follow-up. Such improve-
ment could reduce the development and progression of the
chronic complications of diabetes [2–5], resulting in an
ultimate reduction of the cost of patient care [1,6,7]. The
inconsistent profile of HbA1c, systolic blood pressure and
triglyceride values observed in patient records from all
groups before starting the PRODIACOR study (Figs 3–4)
indicates that the improvement can be ascribed to the
educational interventions rather than to a simple regression
to the mean values. These improvements were not associated
with significant changes in BMI, suggesting that patients and
physicians were more prone to adhering to drug treatment
than to adopting healthy lifestyle habits.
Even although psychological support was not provided,
the WHO-5 scores initially recorded had significantly
improved by the end of the study, with no significant
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FIGURE 4 Changes in serum triglyceride levels (mg/dl). Points represent the mean  SEM of serum triglyceride levels recorded in each group at a
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Table 1); additionally, significant differences (P < 0.05) were recorded at time 7 [patient and physician education (group 4) vs. control group with
no patient or physician education (group 1) and patient education (group 3)].
Table 2 Well-being questionnaire
WHO-5 Well-Being Index (9 4)
Group 1*
(control group)
Group 2 (physician
education)
Group 3 (patient
education)
Group 4 (patient and
physician education) P†
Basal 18 (0–48) 24 (0–64) 16 (0–48) 16 (0–48) 0.407
Final 48 (16–80) 48 (22–80) 48 (16–80) 52 (16–80) 0.797
P‡ 0.0042 0.0051 0.0039 0.0033
Thresholds suggested by Lowe et al. were used to analyse the results of the WHO-5 questionnaire [27]; accordingly, scores ≤ 28 suggest the
need of immediate psychological support; scores between 29 and 50 require further assessment of psychological status; and scores ≥ 51 do
not require psychological support. Data are presented as median (interquartile range).
*Group 1, control group with no patient or physician education.
†Kruskal–Wallis test.
‡Wilcoxon’s signed-rank test.
ª 2013 The Authors.
Diabetic Medicine ª 2013 Diabetes UK 7
Research article DIABETICMedicine
differences among groups. These data suggest that both the
care and the educational strategies implemented provided
some psychological support, which, in many cases, reduced
the negative psychological impact of the disease.
Several authors have shown in many populations that
educational programmes with a theoretical basis using
cognitive reframing are associated with improved outcomes
[22,28,29]. A structured group education programme for
patients with newly diagnosed Type 2 diabetes (the DES-
MOND study) resulted in greater improvements in weight
loss and smoking cessation and in positive beliefs about
illness, but had no effect on HbA1c up to 12 months after
diagnosis [30]. It also showed that the programme was cost-
effective (with 66% using trial-based intervention costs and
70% using ‘real world’ costs) at a threshold of £20 000 per
quality-adjusted life year. Brownson et al. also reported that
self-management programmes for Type 2 diabetes imple-
mented at the primary care level were cost-effective from the
perspective of a healthcare system, when considering cost
savings as a result of reductions in long-term complications
[31]. In our case, all the educational interventions tested
significantly improved the primary outcomes. Altogether, the
evidence strongly suggests that education, regardless of the
method used, is an effective tool to improve the care and
outcomes of people with Type 2 diabetes.
We demonstrated that, although educational strategies
directed to different audiences (patients, physicians or com-
bined implementation) were effective in achieving many
therapeutic goals, their relative efficacy was not the same. In
fact, the implementation of the combined education of
patients and physicians provided the greatest as well as the
most consistent and sustained clinical and metabolic improve-
ment at the best drug treatment cost-effective ratio. Such
characteristics, only recorded in this group, would enhance
the prevention power of the clinical and metabolic improve-
ment associated with the combined education strategy. In
addition, physician education occupied the second position in
magnitude of induced changes; this is not a minor point as the
study was dealing with primary care physicians, this being the
level suitable to start the promotion of early diagnosis as well
as timely and appropriate diabetes treatment.
Despite the evidence of improvement of diabetes outcomes
using educational interventions reviewed here and demon-
strated in this paper, some authors claim that the long-term
effectiveness of educational interventions in people with
Type 2 diabetes remains unproven [19]. Perhaps this scep-
ticism underlies the reason why educational interventions are
prescribed at a significantly lower rate than other prevention
strategies [11]. Further, in one systematic review, the authors
concluded that more studies were needed, particularly on the
long-term benefit of educational interventions [19]. Recently,
a long-term multi-centre, 13-hospital trial was implemented
in Italy by Trento et al., aimed at improving diabetes control
through lifestyle intervention in 815 patients with recently
diagnosed Type 2 diabetes [32]. These authors found that, in
the intervention group, healthcare behaviours, quality of life
and knowledge of diabetes were significantly better than in
the control subjects. Additionally, they had lower HbA1c,
total cholesterol, LDL cholesterol, triglyceride, systolic blood
pressure and diastolic blood pressure, BMI and serum
creatinine, and higher HDL cholesterol than control subjects
despite receiving a similar pharmacological treatment. The
data presented herein further support these conclusions in
primary care settings and in people with 10-year average
Type 2 diabetes duration.
While our data show a significant improvement in quality
of care and optimization of economic investment, particu-
larly in drug costs, they are limited by the possibilities that:
Table 3 Costs of drug treatment
Variable
Group 1*
(control group)
Group 2 (physician
education)
Group 3 (patient
education)
Group 4 (patient and
physician education)
Hyperglycaemia(HbA1C)
† Initial cost 332 400 151 230
Final cost 540 516 314 365
D $ 208 116 163 135
D HbA1c% –0.38 –0.68 –0.34 –0.84
D$/1% HbA1c decrease 547 171 479 161
Initial cost 116 100 115 122
Hypertension Final cost 208 129 165 148
D $ 92 29 50 36
D mmHg –12 –2 –9 –16
D$/10 mmHg decrease 77 145 56 23
Initial cost 74 94 189 85
Triglycerides Final cost 172 170 236 163
D $ 98 76 47 78
D mg/dl 18 –12 –3 –18
D$/10 mg/dl decrease 54 63 157 43
Data are shown as mean values; D in $ were also expressed as the amount necessary to decrease an arbitrary unit selected for each variable.
*Group 1, control group with no patient or physician education.
†For this estimation, D HbA1c is expressed in Diabetes Control and Complications Trial (DCCT) units.
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(1) the physicians collecting the data were not blinded to
outcomes, with the carrying forward of last data for primary
endpoint; (2) the full healthcare coverage simultaneously
provided to all PRODIACOR participants, irrespective of the
group allotted, could be partly responsible for the improve-
ments obtained; and (3) the cost analysis should consider not
only drug costs but also other costs, including those directly
related to the educational interventions themselves.
In brief, our data show that long-term implementation of
different targeted educational interventions at the primary
care level in people with Type 2 diabetes of long duration
significantly improved clinical, metabolic and psychological
outcomes at a reasonably marginal cost. Even the simple
provision of structured written information and the imple-
mentation of a continuous monitoring of quality of care,
associated with periodic feedback reports for patients and
physicians [the control group with patients and physicians
not educated (group 1)] resulted in significant improvements;
the high motivation of patients and physicians would have
been partially responsible for the success in this group. This
is not a minor issue, particularly for developing countries
that are facing a continuous growth of diabetes prevalence
without a parallel increase in their healthcare budgets.
Maximal effect at lower economic cost was seen when
education was simultaneously delivered to people with
diabetes and their healthcare providers; i.e. when both sides
share common aims. Further, the importance of including
physician education to optimize treatment-target goals is also
shown. As the participating organizations operate at national
level and the public healthcare sector is common to each
province of Argentina, the successful outcomes of this model
could be easily reproduced in other provinces. It could be
also adapted and adopted by other developing countries with
similar healthcare settings. Such implementation would
result in better outcomes and in the optimization of drug
consumption, making feasible secondary prevention and the
improvement of the quality of life of people with diabetes.
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Appendix
List of study participants
General Coordinator of PRODIACOR: J. J. Gagliardino.
Local Coordinator in Corrientes: S. Lapertosa. Executive
Committee at CENEXA: N. V. Cedola, C. Gonzalez, J. E.
Caporale, E. Rucci, L. Gonzalez, A. Sanchez. Executive
Committee at Corrientes: P. Torales, M. A. Yordan and
J. Murua, Unidad de Gestion y Participacion, Programa de
Atencion Medica Integral (UGP-PAMI); M. Villagra, Health
Ministry of Corrientes; G. Ojeda, Sistema de Prevencion
Social (SPS); A. Valmagia and A. Silva, Programa Federal de
Salud (PROFE); D. Dos Santos, Health Ministry of Corrien-
tes; C. Segersbol, B. De la Vega, A. Karatanazopulos, R.
Esquercia and R. Degregorio, Instituto Obra Social de
Corrientes (IOSCOR); F. Marcopulos, J. Migueles and M.
Polimeni, Obra Social para la Actividad Docente (OSPLAD).
Intersectorial Committee at Corrientes: R. Cardozo and R.
Pinchetti, Health Ministry of Corrientes; I. Rigonatto,
Instituto Nacional de Servicios Sociales para Jubilados y
Pensionados (INSSJYP); D. Mondaini, Universidad Nacional
del Nordeste; B. Benitez, Sociedad Argentina de Cardiologıa,
Corrientes; D. Dionisi, Sociedad Argentina de Diabetes,
Northeast Chapter. National Advisory Committee: J.M.
Domınguez. International Advisory Committee: C. Clark
Jr, Indiana University.
The forms and questionnaires used in the study are
available upon request (direccion@cenexa.org).
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